Short answer
Arbutus Biopharma Corp (ABUS) filed an 8-K current report with the SEC on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Third-quarter financial results for period ended September 30, 2026 announced.
Arbutus Biopharma Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Third-quarter financial results for period ended September 30, 2026 announced
- Investor-relevant details, including revenue, expenses and cash position, contained in Exhibit 99.1
- Results provide updated view of Arbutus’s operating performance and liquidity during fiscal 2026
Item EX-99.1 · Exhibit EX-99.1
- Cash and marketable securities $337.5M at September 30, up from $91.5M, strengthening funding for clinical programs
- $230M tender offer repurchased 46M shares at $5.00, approximately 23% of outstanding shares, materially reducing share count
- Q3 net income $59.1M, or $0.30 per diluted share, versus a $7.7M loss, driven primarily by $67.3M Genevant dividend income
- FDA lifted AB-101 clinical hold, reopening U.S. development of the oral PD-L1 inhibitor
- New Japan lawsuits and expanded Canadian claims increase potential LNP litigation recoveries, while adding enforcement costs and uncertainty
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Arbutus Biopharma Corp 8-K filings
Get the next ABUS 8-K as it lands
Follow ABUS for push alerts, or ask the research agent what this filing means.